Search

Your search keyword '"Gliomas -- Drug therapy"' showing total 756 results
Start Over Descriptor "Gliomas -- Drug therapy" Database Gale General OneFile
756 results on '"Gliomas -- Drug therapy"'

1. His Brain Tumor Was a Hopeless Case. Then an Experimental Medicine Made It Melt Away. IMMUNOTHERAPY IS CHANGING CANCER TREATMENT FOREVER

Author

Cox, Christopher

Subjects
Gliomas -- Drug therapy, Immunotherapy, B cells, Brain tumors -- Drug therapy, Cancer -- Care and treatment, General interest, News, opinion and commentary
Abstract

One morning at the end of April 2023, Marcela Maus, a cancer researcher at Mass General in Boston, got a call from her colleague Bryan Choi. 'He called me, and [...]

Published
2024

2. Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer

Subjects
Brain research, Oncology, Experimental, T cells, Immunotherapy, Gliomas -- Drug therapy, Cancer -- Care and treatment -- Drug therapy -- Research, Charitable trusts, Vaccines, Arts and entertainment industries
Abstract

The Wistar Institute's David B. Weiner, Ph.D. Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research and his lab [...]

Published
2024

3. Data from Nagasaki University Broaden Understanding of siRNA-Based Therapy (10065- Et-6 Mrna-encapsulated Lipid Nanoparticles For Malignant Glioma)

Subjects
Drugs -- Vehicles, Nanoparticles -- Dosage and administration, Messenger RNA -- Usage -- Evaluation, Gliomas -- Drug therapy, Drug delivery systems -- Methods -- Evaluation, Health
Abstract

2024 DEC 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on siRNA-based therapy have been presented. According to news reporting [...]

Published
2024

4. Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer

Subjects
Brain research, Oncology, Experimental, T cells, Immunotherapy, Gliomas -- Drug therapy, Cancer -- Care and treatment -- Drug therapy -- Research, Charitable trusts, Vaccines, Arts and entertainment industries
Abstract

The Wistar Institute's David B. Weiner, Ph.D. Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research and his lab [...]

Published
2024

5. New strategy puts targets on brain cancer cells

Subjects
Immunotherapy, Gliomas -- Drug therapy, Cancer -- Care and treatment, Drug approval, Brain cancer -- Drug therapy
Abstract

In a cell-based study, researchers have forced glioblastoma cells to display immune system targets. The new strategy could potentially make them visible to immune cells and newly vulnerable to immunotherapies. [...]

Published
2024

6. Studies from University of Manchester Have Provided New Data on Brain Cancer (Tackling Anticancer Drug Resistance and Endosomal Escape In Aggressive Brain Tumors Using Bioelectronics)

Subjects
University of Manchester -- Reports, Brain research -- Reports, Vincristine -- Reports, Chemotherapy -- Reports, Cancer -- Chemotherapy -- Research, Drug delivery systems -- Reports, Physical fitness -- Reports, Brain -- Reports, Oncology, Experimental -- Reports, Drugs -- Vehicles, Entrapment (Criminal law) -- Reports, Drug resistance -- Drug therapy, Gliomas -- Drug therapy, Nanotechnology -- Reports, Brain cancer -- Drug therapy
Abstract

2024 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Oncology - Brain Cancer is now available. According [...]

Published
2024

8. Researchers from Dana-Farber Cancer Institute Detail New Studies and Findings in the Area of Gliomas (The Role of Mutant idh Inhibitors In the Treatment of Glioma)

Subjects
Oncology, Experimental -- Health aspects -- Reports, Gliomas -- Drug therapy, Cancer -- Drug therapy -- Research, Physical fitness -- Health aspects -- Reports, Health
Abstract

2024 OCT 19 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Oncology - Gliomas. According to news reporting [...]

Published
2024

9. Investigators from University of Newcastle Report New Data on Gliomas (Current Status and Advances To Improving Drug Delivery In Diffuse Intrinsic Pontine Glioma)

Subjects
Oncology, Experimental -- Reports, Drugs -- Vehicles, Gliomas -- Drug therapy, Brain tumors -- Drug therapy, Cancer -- Research, Drug delivery systems -- Reports, Physical fitness -- Reports, Health
Abstract

2024 SEP 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Oncology - Gliomas have been presented. According to news [...]

Published
2024

10. Data from Wayne State University School of Medicine Update Knowledge in Gliomas (Complete radiographic response after proton radiation therapy in the re-irradiation of a diffuse high-grade glioma: A case report)

Subjects
Antineoplastic agents, Gliomas -- Drug therapy, Radiation, Brain tumors -- Drug therapy, Radiotherapy, Physical fitness, Antimitotic agents, Health
Abstract

2024 SEP 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on gliomas. According to news originating from Detroit, [...]

Published
2024

11. Shuttle Pharmaceuticals gets ODD for IPdR to treat brain tumors

Subjects
Gliomas -- Drug therapy, Brain tumors -- Drug therapy, Business, News, opinion and commentary
Abstract

Shuttle Pharmaceuticals Holdings provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30 .Shuttle Pharma's recent highlights [...]

Published
2024

14. Telix announces opening of expanded access program in U.S. for TLX101-CDx

Subjects
United States. Food and Drug Administration, Practice guidelines (Medicine), Gliomas -- Drug therapy, Brain tumors -- Drug therapy, Drug approval, Business, News, opinion and commentary
Abstract

Telix Pharmaceuticals announces the opening of an expanded access program in the United States for TLX101-CDx, an investigational positron emission tomography agent for imaging progressive or recurrent glioma, following U.S. [...]

Published
2024

16. Data on Gliomas Discussed by a Researcher at Northwestern University Feinberg School of Medicine (The biological significance of tumor grade, age, enhancement and extent of resection in IDH mutant gliomas: how should they inform treatment ...)

Subjects
Gliomas -- Drug therapy, Physical fitness -- Reports, Surgery -- Reports, Health, World Health Organization -- Reports
Abstract

2024 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on gliomas are discussed in a new report. According to [...]

Published
2024

17. Researchers at Polish Academy of Sciences Have Reported New Data on Brain Cancer (Inhibitors of Ck2 Kinase for the Treatment of Gliomas and Other Brain Tumors)

Subjects
Oncology, Experimental, Brain research, Gliomas -- Drug therapy, Brain cancer -- Drug therapy, Cancer -- Research, Physical fitness, Health
Abstract

2024 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Oncology - Brain Cancer. According to news [...]

Published
2024

19. Tackling Anticancer Drug Resistance and Endosomal Escape in Aggressive Brain Tumors Using Bioelectronics

Subjects
Drug dealing, Drug resistance -- Drug therapy, Gliomas -- Drug therapy, Brain tumors -- Drug therapy, Vincristine, Drug traffic, Chemotherapy, Cancer -- Chemotherapy, Physical fitness, Health
Abstract

2024 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2024

20. Candel Reports FDA Grants Orphan Drug Designation to CAN-3110

Subjects
United States. Food and Drug Administration, Orphan drugs, Gliomas -- Drug therapy, Immunotherapy, Arts and entertainment industries
Abstract

Candel Therapeutics, a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, reported that the U.S. Food and Drug Administration (FDA) has granted Orphan [...]

Published
2024

21. Candel Therapeutics receives Orphan Drug Designation for CAN-3110

Subjects
United States. Food and Drug Administration, Orphan drugs, Gliomas -- Drug therapy, Business, News, opinion and commentary
Abstract

Candel Therapeutics announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to CAN-3110, a next generation oncolytic viral immunotherapy, for the treatment of recurrent high-grade glioma. [...]

Published
2024

23. Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer

Subjects
Brain research, Oncology, Experimental, T cells, Immunotherapy, Gliomas -- Drug therapy, Cancer -- Care and treatment -- Drug therapy -- Research, Charitable trusts, Vaccines, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Trispecific Design Controls Glioblastoma Tumors in Preclinical Models PHILADELPHIA, PA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- PHILADELPHIA -- (December 3, 2024) -- The Wistar Institute's [...]

Published
2024

24. STUDY IDENTIFIES NOVEL APPROACH TO OVERCOME THE BLOOD-BRAIN BARRIER IN PEDIATRIC GLIOMA TREATMENT

Subjects
Brain -- Reports, Oncology, Experimental -- Reports, Pediatrics -- Reports, Stem cells -- Reports, Gliomas -- Drug therapy, Brain tumors -- Drug therapy, Radiotherapy -- Reports, Cancer -- Research, News, opinion and commentary
Abstract

NEW YORK, NY -- The following information was released by Columbia University: A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) has identified a [...]

Published
2024

25. STUDY REVEALS HOW DEADLY BRAIN TUMOR EVADES TREATMENT; IDENTIFIES POTENTIAL NEW TREATMENT STRATEGY

Subjects
Brain -- Analysis, Oncology, Experimental -- Analysis, Gliomas -- Drug therapy, Brain tumors -- Drug therapy, Cancer -- Research, News, opinion and commentary
Abstract

LOS ANGELES, CA -- The following information was released by UCLA Health System: A new precision medicine approach that combines genetic and functional profiling helps predict how glioblastoma will respond [...]

Published
2024

26. CELL THERAPY FIGHTS LETHAL CHILDHOOD BRAIN CANCER IN STANFORD MEDICINE TRIAL

Subjects
T cells, Gliomas -- Drug therapy, Children -- Health aspects, Clinical trials, Brain cancer -- Drug therapy, News, opinion and commentary, Stanford University. School of Medicine
Abstract

STANFORD, Calif. -- The following information was released by the Stanford University School of Medicine: CAR-T cells show promise against pediatric diffuse midline gliomas, brain and spinal cord tumors that [...]

Published
2024

27. CAR-T CELLS SHOW PROMISE AGAINST PEDIATRIC DIFFUSE MIDLINE GLIOMAS, BRAIN AND SPINAL CORD TUMORS THAT ARE AMONG THE DEADLIEST CANCERS, A STANFORD MEDICINE TRIAL FOUND

Subjects
Pediatrics, T cells, Gliomas -- Drug therapy, Brain tumors -- Drug therapy, Children -- Health aspects, Cancer -- Drug therapy, News, opinion and commentary, Stanford University. School of Medicine
Abstract

STANFORD, Calif. -- The following information was released by the Stanford University School of Medicine: By Erin Digitale Crystal Mackall, left, and Michelle Monje led a clinical trial of an [...]

Published
2024

28. Aitia Expand Collaboration with Servier to Discover and Develop New Drugs for Brain Cancer Using AI-Driven Digital Twins

Subjects
Brain, Twins, Drug discovery, Gliomas -- Drug therapy, Brain tumors -- Drug therapy, Cancer -- Drug therapy, General interest, News, opinion and commentary
Abstract

SOMERVILLE: Aitia has issued the following press release: Aitia, a biotech company pioneering the use of causal AI and Digital Twins in drug discovery and development, is expanding its collaboration [...]

Published
2024

29. MAPK Pathway Inhibitors Augment Treatments for Pediatric Low-Grade Gliomas

Author

Cohen, Kenneth J.

Subjects
Pediatrics, Gliomas -- Drug therapy, Vincristine, Drug approval, Health
Abstract

The goal of treatment in pediatric low-grade gliomas is to cure patients of the disease, which is an achievable outcome in this setting. Kenneth J. Cohen, MD, MBA, is a [...]

Published
2023

30. Xoma earns $9M milestone as FDA grants approval of Day One's NDA for OJEMDA

Subjects
United States. Food and Drug Administration, XOMA Corp., Biological products, Gliomas -- Drug therapy, Drug approval, Pharmaceutical industry, Business, News, opinion and commentary
Abstract

XOMA Corporation (XOMA) announced it has earned a $9 million milestone related to the U.S. Food and Drug Administration's, FDA, approval of Day One Biopharmaceuticals' (DAWN) New Drug Application, NDA, [...]

Published
2024

32. Rzeszow University of Technology Researchers Provide New Study Findings on Gliomas (Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents-Comparative Studies on Normal and ...)

Subjects
Temozolomide -- Reports -- Comparative analysis, Gliomas -- Drug therapy, Amino acids -- Reports -- Comparative analysis, Celecoxib -- Reports -- Comparative analysis, Physical fitness -- Comparative analysis -- Reports, Health
Abstract

2024 APR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on gliomas are presented in a new report. According to [...]

Published
2024

33. New Findings from Ningxia Medical University in the Area of Gliomas Described (Inhibitor of Wnt Receptor 1 Suppresses the Effects of Wnt1, Wnt3a and B-catenin On the Proliferation and Migration of C6 Gscs Induced By Low-dose Radiation)

Subjects
Stem cells -- Analysis, Gliomas -- Drug therapy, Radiation -- Analysis, Health
Abstract

2024 FEB 26 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- Current study results on Oncology - Gliomas have been published. According to news originating [...]

Published
2024

34. Vorasidenib Under Review for Isocitrate Dehydrogenase-Mutant Diffuse Glioma

Author

Duffy, Steve

Subjects
United States. Food and Drug Administration, Gliomas -- Drug therapy, Health
Abstract

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for vorasidenib for the treatment of isocitrate dehydrogenase- (IDH)-mutant diffuse glioma. Vorasidenib is an [...]

Published
2024

35. Researcher from German Cancer Research Center (DKFZ) Reports Details of New Studies and Findings in the Area of Personalized Medicine (Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with ...)

Subjects
Oncology, Experimental, Gliomas -- Drug therapy, Prescription writing, Cancer -- Drug therapy -- Research, Health
Abstract

2025 JAN 3 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in personalized medicine. According to news reporting out of [...]

Published
2025

36. Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer

Subjects
Brain research, Oncology, Experimental, T cells, Immunotherapy, Gliomas -- Drug therapy, Cancer -- Care and treatment -- Drug therapy -- Research, Charitable trusts, Vaccines, Business, Business, international, Telecommunications industry
Abstract

The Wistar Institute's David B. Weiner, Ph.D. Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research and his lab [...]

Published
2024

37. Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer

Subjects
Brain research, Oncology, Experimental, T cells, Immunotherapy, Gliomas -- Drug therapy, Cancer -- Care and treatment -- Drug therapy -- Research, Charitable trusts, Vaccines, Business, Business, international, Telecommunications industry
Abstract

The Wistar Institute's David B. Weiner, Ph.D. Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research and his lab [...]

Published
2024

38. Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer

Subjects
Brain research, Oncology, Experimental, T cells, Immunotherapy, Gliomas -- Drug therapy, Cancer -- Care and treatment -- Drug therapy -- Research, Charitable trusts, Vaccines, Business, Business, international, Telecommunications industry
Abstract

The Wistar Institute's David B. Weiner, Ph.D. Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research and his lab [...]

Published
2024

39. Shanghai Jiao Tong University School of Medicine Researchers Update Current Data on Gliomas (An integrative analysis based on multiple cell death patterns identifies an immunosuppressive subtype and establishes a prognostic signature in ...)

Subjects
Biochemistry -- Analysis, Cell death -- Analysis, Immunotherapy -- Analysis, Gliomas -- Drug therapy, Health
Abstract

2024 DEC 11 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Researchers detail new data in gliomas. According to news reporting originating from Shanghai, People's Republic [...]

Published
2024

40. Aitia Expand Collaboration with Servier to Discover and Develop New Drugs for Brain Cancer Using AI-Driven Digital Twins

Subjects
Brain, Drug discovery, Gliomas -- Drug therapy, Brain tumors -- Drug therapy, Cancer -- Drug therapy, Business, News, opinion and commentary
Abstract

SOMERVILLE, Mass., Oct. 30, 2024 /PRNewswire/ -- Aitia, a biotech company pioneering the use of causal AI and Digital Twins in drug discovery and development, is expanding its collaboration with [...]

Published
2024

41. FDA Approves NGS-Based Companion Diagnostic for First Targeted Therapy for Patients with Grade 2 IDH-Mutant Glioma

Subjects
United States. Food and Drug Administration, Thermo Fisher Scientific Inc., Scientific equipment and supplies industry, Gliomas -- Drug therapy, Business, international
Abstract

Waltham: Thermo Fisher Scientific, Inc has issued the following press release: Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration [...]

Published
2024

42. FDA Approves NGS-Based Companion Diagnostic for First Targeted Therapy for Patients with Grade 2 IDH-Mutant Glioma

Subjects
United States. Food and Drug Administration, Thermo Fisher Scientific Inc., Scientific equipment and supplies industry, Gliomas -- Drug therapy, Business, Business, international
Abstract

Oncomine Dx Target Test to Identify Patients Eligible for Servier's VORANIGO[R] (vorasidenib) tablet, the only FDA-approved treatment for Grade 2 IDH-mutant glioma CARLSBAD, Calif. -- Thermo Fisher Scientific, the world [...]

Published
2024

43. Amarex Achieves Orphan Drug Designation for Gibson Oncology's Novel LMP744 Cancer Treatment

Subjects
United States. Food and Drug Administration, Orphan drugs, Gliomas -- Drug therapy, Brain tumors -- Drug therapy, Business, Business, international
Abstract

New Designation Marks Milestone in Glioblastoma Treatment Decades in the Making with Glioma Treatment that Crosses Blood Brain Barrier at Ten Times Concentration Needed to Kill Cancer Cells GERMANTOWN, Md. [...]

Published
2024

44. Feasibility of preirradiation temozolomide in cases of high-grade gliomas: Our experience and review of literature

Author

Arora, Savita, Rathi, Arun K., Singh, Kishore, and Ansari, Faiz A.

Subjects
Temozolomide -- Dosage and administration, Gliomas -- Drug therapy
Abstract

ABSTRACT Aim: The purpose of this study was to evaluate the efficacy and safety of preradiation temozolomide (TMZ) in high-grade gliomas. Study and Design: It is a single-center, single arm, prospective study. The study included postoperative, histopatholgically proven cases of high-grade gliomas. Materials and Methods: Nine patients of anaplastic astrocytoma (AA) and twenty patients of glioblastoma multiforme (GBM) were enrolled in the study. All patients had undergone partial or complete resection. Three weeks after surgery, patients were started on chemotherapy, consisting of two cycles of TMZ, 150 mg/m[sup.2]/day for 5 days, repeated at an interval of 4 weeks. Patients were subsequently treated with concomitant chemoradiotherapy. A dose of 60 Gy was given over thirty fractions along with TMZ, 75 mg/m[sup.2]/day. Four cycles of TMZ were given after completion of radiotherapy, in a dose and manner similar to preradiotherapy. Statistical Analysis and Result: Treatment-related toxicity was assessed using common terminology for toxicity criteria (CTCAE v4). Progression-free survival and overall survival (OS) analysis was done. Nearly 79 of patients completed the two cycles of preradiation chemotherapy. Chemotherapy was tolerated well. Median time to progression was 11 months and 8.2 months in AA and GBM patients, respectively. Median OS was 17.4 months in AA patients and 11.4 months in GBM patients. Conclusions: Most patients of postoperative high-grade gliomas tolerated two cycles of TMZ. A good safety profile of TMZ allows it to be used in frontline settings, especially in high volume centers where a delay in starting radiotherapy frequently occurs. The use of TMZ before radiotherapy is a safe and feasible approach, and further studies are required to validate this approach. Keywords: High-grade glioma, preradiation chemotherapy, temozolomide, Author(s): Savita Arora (corresponding author) [1]; Arun K. Rathi [1]; Kishore Singh [1]; Faiz A. Ansari [1] INTRODUCTION The current standard of care for high-grade gliomas (HGG) patients is maximal [...]

Published
2023
Full Text
View/download PDF

48. Tovorafenib Under Review for Relapsed or Progressive Pediatric Low-Grade Glioma

Author

Park, Brian

Subjects
United States. Food and Drug Administration, Pediatrics, Gliomas -- Drug therapy, Health
Abstract

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for tovorafenib for the treatment of relapsed or progressive pediatric low-grade glioma (pLGG). Tovorafenib [...]

Published
2023

49. Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA

Subjects
United States. Food and Drug Administration, Gliomas -- Drug therapy, Brain tumors -- Drug therapy, Business
Abstract

M2 EQUITYBITES-August 28, 2024-Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Telix Pharmaceuticals Limited (ASX: TLX), an Australia-based biopharmaceutical company, announced on Wednesday that it has [...]

Published
2024

50. Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA

Subjects
United States. Food and Drug Administration, Gliomas -- Drug therapy, Brain tumors -- Drug therapy, Chemistry
Abstract

M2 PHARMA-August 28, 2024-Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA (C)2024 M2 COMMUNICATIONS Telix Pharmaceuticals Limited (ASX: TLX), an Australia-based biopharmaceutical company, announced on Wednesday that it has submitted [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results